BioShield II May Revive Big Pharma’s Interest In Biodefense
Executive Summary
The proposed "BioShield II" legislation is reviving big pharma's interest in the biodefense industry, McKenna Long & Aldridge Partner Frank Rapoport maintained March 3 at Equity International's Homeland & Global Security Summit in Washington, D.C
You may also be interested in...
Pfizer Names Bush Cabinet Veteran Principi To Head Government Affairs
Former Veterans Affairs Secretary Anthony Principi will replace Pfizer VP-Government Relations Kenneth Bowler as head of the company's government affairs staff effective March 15
Pfizer Names Bush Cabinet Veteran Principi To Head Government Affairs
Former Veterans Affairs Secretary Anthony Principi will replace Pfizer VP-Government Relations Kenneth Bowler as head of the company's government affairs staff effective March 15
Roche Vision Of Rx Future Includes IT And China, But Not Large Sales Force
Roche is keeping a close watch on information technology companies as potential emerging competitors for the pharmaceutical industry, CFO Erich Hunziker told the recent J.P. Morgan health care conference in San Francisco